TY - JOUR
T1 - Brimonidine tartrate
T2 - A one-month dose response study
AU - Derick, R. J.
AU - Robin, A. L.
AU - Walters, T. R.
AU - Barnebey, H. S.
AU - Choplin, N.
AU - Schuman, J.
AU - Kelley, E. P.
AU - Chen, K.
AU - Stoecker, J. F.
N1 - Funding Information:
Originally received: January 9, 1996. Revision accepted: August 5, 1996. 1 Sinai Hospital, Baltimore. . 2 Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore. 3 Austin, Texas. 4 Seattle, Washington. 5 The Naval Hospital, San Diego. 6 New England Eye Center, Boston. 7 Allergan, Inc, Irvine. Dr. Derick is currently affiliated with the William H. Havener Eye Center, The Ohio State University, Columbus, Ohio. Presented in part at the ARVO Annual Meeting, Sarasota, April 1993. Supported in part by a grant from the Zanvyl Krieger Foundation and Allergan, Inc. Drs. Derick, Walters, Robin, Bamebey, Schuman, and Choplin have no
PY - 1997
Y1 - 1997
N2 - Background: Brimonidine tartrate is a relatively selective alpha2- agonist that effectively reduces mean intraocular pressure (IOP) and the incidence of IOP spikes after laser trabeculoplasty. The authors were interested in evaluating the dose response of brimonidine when applied topically for a longer duration in patients with elevated IOPs. Methods: The authors conducted a 1-month, multicentered, double-masked, randomized, placebo-controlled, parallel clinical study in 194 patients with ocular hypertension or glaucoma (mean IOP, 25.6 ± 3.2 mmHg). The authors administered three concentrations of brimonidine (0.08%, 0.2%, and 0.5%) or placebo bilaterally every 12 hours for 1 month. The authors evaluated the following parameters: IOP, heart rate, blood pressure, visual acuity, pupil size, basal tear secretion as well as patient comfort at baseline, day 1, week 1, week 3, and week 4. Results: All concentrations of brimonidine significantly reduced IOP, compared to baseline and placebo, at all follow- up visits. Maximum mean IOP decreases from baseline of 20.8%, 27.2%, and 30.1% were observed for the 0.08%, 0.20%, and 0.5% treatment groups, respectively. On days 1 and 21, the 0.2% and 0.5% treatment groups exhibited significantly greater IOP decreases than did the 0.08% group. After the initial steep decline in IOP, the effect decreased slightly and stabilized at day 14 at the level that was maintained throughout the study. The most frequent side effects reported were fatigue and dry mouth. No significant changes in heart rate were reported. Statistically significant decreases in mean blood pressure without clinical symptoms were observed within the 0.2% and 0.5% treatment groups. Conclusion: Brimonidine 0.2% is well tolerated, efficacious, and shows potential as an agent in the long-term treatment of elevated IOP.
AB - Background: Brimonidine tartrate is a relatively selective alpha2- agonist that effectively reduces mean intraocular pressure (IOP) and the incidence of IOP spikes after laser trabeculoplasty. The authors were interested in evaluating the dose response of brimonidine when applied topically for a longer duration in patients with elevated IOPs. Methods: The authors conducted a 1-month, multicentered, double-masked, randomized, placebo-controlled, parallel clinical study in 194 patients with ocular hypertension or glaucoma (mean IOP, 25.6 ± 3.2 mmHg). The authors administered three concentrations of brimonidine (0.08%, 0.2%, and 0.5%) or placebo bilaterally every 12 hours for 1 month. The authors evaluated the following parameters: IOP, heart rate, blood pressure, visual acuity, pupil size, basal tear secretion as well as patient comfort at baseline, day 1, week 1, week 3, and week 4. Results: All concentrations of brimonidine significantly reduced IOP, compared to baseline and placebo, at all follow- up visits. Maximum mean IOP decreases from baseline of 20.8%, 27.2%, and 30.1% were observed for the 0.08%, 0.20%, and 0.5% treatment groups, respectively. On days 1 and 21, the 0.2% and 0.5% treatment groups exhibited significantly greater IOP decreases than did the 0.08% group. After the initial steep decline in IOP, the effect decreased slightly and stabilized at day 14 at the level that was maintained throughout the study. The most frequent side effects reported were fatigue and dry mouth. No significant changes in heart rate were reported. Statistically significant decreases in mean blood pressure without clinical symptoms were observed within the 0.2% and 0.5% treatment groups. Conclusion: Brimonidine 0.2% is well tolerated, efficacious, and shows potential as an agent in the long-term treatment of elevated IOP.
UR - http://www.scopus.com/inward/record.url?scp=0031056490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031056490&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(97)30349-2
DO - 10.1016/S0161-6420(97)30349-2
M3 - Article
C2 - 9022117
AN - SCOPUS:0031056490
SN - 0161-6420
VL - 104
SP - 131
EP - 136
JO - Ophthalmology
JF - Ophthalmology
IS - 1
ER -